Alejandro J. Lavaque, MD
Vitreo-retinal Fellow
New England
Retina Associates
Connecticut, USA |
Exudative Age-related Macular Degeneration - Part 1
Pharmacological Inhibition of Vascular Endothelial
Growth Factor (VEGF)
Volume 33, Number # 4, 2005 Series
Alejandro J. Lavaque, MD
Vitreo-retinal Fellow
New England
Retina Associates
Connecticut, USA |
1. Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13:806-811.
2. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5 (suppl 1):3-10.
3. Ferrara N. Role of Vascular Endothelial Growth Factor in Physiologic and Pathologic Angiogenesis: Therapeutic Implications. Semin Oncol 2002;29:10-14.
4. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growht factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
5. Alon T, Hemo I, Itin A, et al. Vascular endothelial growht factor acts as a survival factor for newly formed retinal vessels and has implications for retinopahty of prematurity. Nat Med 1995;1.
6. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
7. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259-270.
8. Rosen LS. Clinical Experience With Angiogenesis Signaling Inhibitors: Focus on Vascular Endothelial Growth Factor (VEGF) Blockers. Cancer Control 2002;9:36-44.
9. Jain RK. Tumor Angiogenesis and Accessibility: Role of Vascular Endothelial Growth Factor. Semin Oncol 2002;29:3-9.
10. Angiogenesis Foundation. Understanding angiogenesis. Available at: http://www.angio.org/understanding/content_understanding.html. Accessed December 20, 2004.
11. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-293.
12. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
13. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003;42:81-91.
14. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitions in tumor invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062-2072.
15. Holz FG, Miller DW. Pharmacological therapy for age-related macular degeneration. Current developments and perspectives. Ophthalmologe 2003;100:97-103.
16. The Anecortave Acetate Clinical Study Group. Anecortave Acetate as Monotherapy for the Treatment of Subfoveal Lesions in Patients with Exudative Age-related Macular Degeneration (AMD). Interim (6 months) Analysis of Clinical Safety and Efficacy. Retina 2003;23:14-23.
17. The Eyetech Study Group. Anti-vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Sedondary to Age-related Macular Degneration. Phase II Study Results. Ophthalmology 2003;110:979-986.
18. Bhutto IA, Kim SY, McLeod DS, al.. e. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:1544-1552.
19. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997;115:865-872.
20. Ciardella AP, Donsoff IM, Guyer DR, et al. Antiangiogenesis agents. Opthalmol Clin North Am 2002;15:453-458.
21. Ciulla TA, Criswell MH, Danis RP, et al. Squalamine Lactate Reduces Choroidal Neovascularization in a Laser-injury Model in the Rat. Retina 2003;23:808-814.
|
